The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
More and more fit individuals are turning to microdoses of GLP-1s, drawn by potential health benefits beyond weight loss. While some see it as a proactive approach to longevity, experts caution about the lack of research and potential risks.
Eli Lilly has announced price cuts for its weight loss medication Zepbound, aiming to improve accessibility for patients. The company is also seeking to increase the use of its digital healthcare platform, LillyDirect, through these changes.
The World Health Organization (WHO) has issued new guidelines advocating for the use of GLP-1 drugs in the treatment of obesity. These guidelines suggest that GLP-1 therapies can be used long-term by adults, excluding pregnant women, when combined with intensive behavioral therapy.
A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
Blockbuster weight-loss shots are evolving, with new treatments in development that aim to improve upon current injections. Drugmakers are developing a new wave of GLP-1 treatments, with several promising candidates in the pipeline. These experimental treatments aim to address some of the biggest gripes about today's injections.
